Navigation Links
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
Date:8/28/2013

SAN DIEGO, Aug. 28, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by utilizing the FDA 505(b)(2) development pathway, has announced it has acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation has the potential to significantly impact the fast-growing $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities. 

Imprimis CEO, Mark L. Baum, said, "This is an important acquisition of a novel drug formulation with an important clinical track record. It is gratifying to see our Asset Review Methodology (ARM™) at work. We believe that going forward our growing group of drug discovery and development relationships will bring additional clinically relevant formulations to our company, and these assets will drive additional value for our shareholders. We are in the process of conducting a feasibility assessment related to the development of this asset, together with a team which consists of leaders from the ophthalmic development and regulatory community. Imprimis will continue to develop partnerships with inventors and secure assets which will support our strategic objectives."

The target compound, referred to as IPI-140, is based on a novel combination of moxifloxacin and triamcinolone.  IPI-140 was co-invented b
'/>"/>

SOURCE Imprimis Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
2. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
3. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
4. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
5. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
6. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
7. Imprimis Announces Key Leadership Appointments
8. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
9. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
10. Imprimis to Begin New Study of Its Topical Analgesic Drug
11. Imprimis Names Two Experts To Its Science And Regulatory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye, today ... 2014 Medical Technology & Diagnostics Forum in ... on Thursday, November 20 at 12:30 p.m. PT/3:30 p.m. ... overview of the Company,s current business trends, financial results, ...
(Date:11/17/2014)... Calif. , Nov. 17, 2014 Asterias ... in the emerging field of regenerative medicine, today announced ... of Research and Development, will participate in a live ... Regenerative Medicine (CIRM) discussing the latest progress in stem ... The CIRM Google Hangout session is scheduled for Tuesday, ...
(Date:11/17/2014)... 17, 2014  CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... investor conferences. Jefferies 2014 Global Healthcare Conference ... EST, London, England . ... December 3 at 9:00 a.m. EST, New York, ... webcast live and available for replay after the presentation. The webcast ...
Breaking Medicine Technology:STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum 2Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury 2CTI BioPharma to Present at the Upcoming Investor Conferences 2
... Edge EHR Corp., EDGE, a provider of Dental ... to announce the release of edgeDMS™ for ... leverage the awesome power of the Apple® iPad. ... (Logo:   http://photos.prnewswire.com/prnh/20100310/AQ68604LOGO ) The ...
... Calif., Dec. 21, 2010 Jazz Pharmaceuticals, Inc. (Nasdaq: ... States Patent and Trademark Office (USPTO) has issued a ... "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for ... is also listed in the FDA,s Approved Drug Products ...
Cached Medicine Technology:Edge EHR Corp. Announces edgeDMS for iPad, Native Touch-Based Clinical Charting Software for the Paperless Dental Office. 2Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate 2
(Date:11/18/2014)... Cristcot Inc., a global life sciences ... specialized drug delivery systems, today announced that the ... for the technology, which encompasses the company’s commercially ... patent was awarded to the inventor Jennifer Davagian ... to Cristcot Inc. The patented technology, titled “Method ...
(Date:11/18/2014)... Medicationdiscountcard.com's blog offers health ... company's reputation for helping consumers save money at ... offer at http://blog.medicationdiscountcard.com/ . , Consumers need ... Affordable Care Act and the state health benefit ... about a variety of prescription drug and health ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... prove effective at lowering LDL ("bad") cholesterol levels for ... That,s the conclusion of a clinical trial presented ... Chicago. The drug, alirocumab, outperformed the on-the-market medication ... statins, Zetia, said lead researcher Dr. Patrick Moriarty, director ...
(Date:11/18/2014)... 2014 (HealthDay News) -- Women who started smoking at ... chronic, severe menstrual pain, a new study suggests. ... While smoking has been suspected as a risk factor ... the authors of the new study said. The ... a long-term study of women,s health in Australia. About ...
(Date:11/18/2014)... 18, 2014 Global Partnership ... the telehealth platform to bring quality healthcare to ... passion, GPT created Global Partnership for TeleHealth Missions ... existing telehealth network. GPTM focuses specifically on ... and disaster relief organizations. , Michael ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2
... a History of Eating Disorders More at Risk for ... for Eating and Anxiety Disorders ( www.remudaranch.com ), the ... new pressure to look perfect while pregnant. "With the ... an increased pressure to look perfect and thin during ...
... is the only authorized online learning program ... Known for bringing innovation to the chiropractic ... only web-based seminar program dedicated exclusively to ... Online, the online learning system authorized by ...
... 19 Abbott announced today,that the U.S. ... the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for ... analyzer. , Cartridges for E3+, ... patient,s,metabolic state within a few minutes. The glucose ...
... Amazing Heat Pack by Comfort Now, Inc., a revolutionary ... pain relief for athletes, arthritics, chronic pain sufferers, premenstrual ... musclesBURLINGTON, Ontario, Jan. 19 Not since the 1920 ... aid product been released as The Amazing Heat Pack, ...
... Commitment to Healthy and Successful Vascular Access for ... Vascular Access(SM), the nation,s leading provider of vascular ... of managed vascular access centers has collectively ,touched, ... Lifeline Vascular Access managed center Nephrology Vascular Lab ...
... The 2008 Frost & Sullivan Technology Innovation Award ... presented to TECNIMED srl for pioneering THERMOFOCUS, the first ... available with a new, rapid, room temperature stabilization system. ... the company that has demonstrated technological superiority within its ...
Cached Medicine News:Health News:Remuda Ranch Reports More Women Seek to Be Thin During Pregnancy 2Health News:Activator Methods Introduces Web-Based Seminar Program 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 3Health News:The Amazing Heat Pack: The Most Innovative First Aid Solution Since the Band-Aid 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 3Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 2Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 3Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 4
... The Vitros 250 is ... meet requirements in multiple environments ... large hospitals, clinics and satellite ... features on-board dilution, and can ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Architect i2000 is a flexible solution for your evolving laboratory providing high throughput and walkaway time with built-in flexibility....
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
Medicine Products: